martes, 30 de agosto de 2011

National Guideline Clearinghouse | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma.

full-text ►
National Guideline Clearinghouse | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma.: Guideline Title

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma.

Bibliographic Source(s)
American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma. Biol Blood Marrow Transplant 2011 Feb;17(2):190-1. PubMed External Web Site Policy

Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL Jr, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010 Apr;16(4):443-68. [85 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

- Enviado mediante la barra Google



Biol Blood Marrow Transplant. 2011 Feb;17(2):190-1. Epub 2010 Dec 4.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma.

PMID:
20940058
[PubMed - indexed for MEDLINE] The role of cytotoxic therapy w... [Biol Blood Marrow Transplant. 2011] - PubMed - NCBI: - Enviado mediante la barra Google




Biol Blood Marrow Transplant. 2010 Apr;16(4):443-68. Epub 2010 Jan 28.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.

Source

Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Abstract

Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of follicular non-Hodgkin lymphoma in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations reached unanimously by a panel of follicular lymphoma experts are: (1) autologous SCT is recommended as salvage therapy based on pre-rituximab data, with a significant improvement in overall survival (OS) and progression-free (PFS) survival; (2) autologous SCT is not recommended as first-line treatment for most patients because of no significant improvement in OS; (3) autologous SCT is recommended for transformed follicular lymphoma patients; (4) reduced intensity conditioning before allogeneic SCT appears to be an acceptable alternative to myeloablative regimens; (5) an HLA-matched unrelated donor appears to be as effective an HLA-matched related donor for reduced intensity conditioning allogeneic SCT. There are insufficient data to make a recommendation on the use of autologous SCT after rituximab-based salvage therapy. Eleven areas of needed research in the treatment of follicular lymphoma with SCT were identified and are presented in the review.
Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
PMID:
20114084
[PubMed - indexed for MEDLINE]

The role of cytotoxic therapy w... [Biol Blood Marrow Transplant. 2010] - PubMed - NCBI: - Enviado mediante la barra Google

1 comentario:

  1. Hello.
    I found your post link in google.com, and I hope you create more post in the future. now I am waiting for your next post.

    Cytotoxic Therapies Market

    ResponderEliminar